Hepatitis B Virus
VIDEO: Both good, bad things can come out of COVID-19 pandemic
Positive anti-HBc linked to cirrhosis, hepatocellular carcinoma in NAFLD
Rheumatology and Primary Care: What is the 95% Confidence Interval of Scope of Practice?

We as rheumatologists are blessed with a surfeit of remarkable therapies and capabilities for controlling disease that we only dreamed about a short generation ago. With these capabilities have come new responsibilities that have — in some ways — stretched our scope of practice. Allow me to discuss just a few examples.
Hepatitis D coinfection found in ‘household clusters’ in Cameroon
Modified PAGE-B score classifies HCC risk in patients undergoing HBV therapy
Diets high in polyunsaturated, vegetable fats reduce liver cancer risk
Study suggests ‘high burden’ of global hepatitis B infection among PLWH
Screen patients with HBV, HCV before treating psoriasis
HDV has higher health care, cost burden than HBV
REP2139 demonstrates functional cure in both HBV, HDV
Results from the REP 301 and REP 401 studies showed combination therapy with REP2139 and pegylated interferon led to high rates of hepatitis B seroconversion in patients coinfected with hepatitis B and hepatitis D with more than half of treated patients also achieving functional cure of hepatitis D, according to data presented at HEP DART 2019.